Prolong Pharmaceuticals Hosts Workshop at the Society for Blood Advancement

SOUTH PLAINFIELD, NJ. September 29, 2016.

Prolong Pharmaceuticals presented at the 2016 Society for Blood Advancement (SABM) meeting in Grand Rapids Michigan.  The Workshop entitled Clinical Use of SANGUINATE in Patients for Whom Blood is Not an Option provided an overview of the use of SANGUINATE followed by the presentation of a case report of a patient who received SANGUINATE for life threatening anemia.

The panel discussion of the case report and factors to consider in clinical trial design for patients for whom blood is not an option included:

  • Abraham Abuchowski, CEO Prolong Pharmaceuticals
  • Cheryl Goss MD – Associate Director of Transfusion Medicine, Memorial Sloan Kettering Cancer Center NY. Physcian who treated patient with SANGUIANTE.
  • Lena Napolitano – Professor of Surgery at the University of Michigan School of Medicine, Division Chief of Acute Care Surgery (Trauma, Burns, Critical Care, Emergency Surgery), Chief of Surgical Critical Care, Program Director of the Surgical Critical Care Fellowship (6 fellows annually) and Associate Chair for the Department of Surgery.
  • Aryeth Shander – Chief of the Department of Anesthesiology, Critical Care Medicine, Pain Management and Hyperbaric Medicine at Englewood Hospital & Medical Center in Englewood, NJ. He is also a Clinical Professor of Anesthesiology, Medicine & Surgery at Icahn School of Medicine at Mount Sinai in New York City, Executive Medical Director of The Institute for Patient Blood Management and Bloodless Medicine and Surgery at Englewood Hospital.
  • Panayiotis Varelas MD – Director of the Neurosciences Intensive Care Unit at Henry Ford Hospital in Detroit, MI, the Neurosciences Intensive Care Unit at Henry Ford West Bloomfield Hospital in West Bloomfield, MI and an Associate Professor of Clinical Neurology at Wayne State University.

“We are pleased that this workshop elicited an in-depth discussion of issues of designing a clinical trial in patients with severe acute anemia who are unable to receive blood transfusions”. Stated Dr. Abuchowski.  “The message from both the audience and panel was that a product to treat life-threatening hypoxia is needed”.

SANGUINATE is currently in clinical trials for a number of indications in which hypoxia and inflammation play a role.  A Phase I safety study in underway in patients with acute, severe anemia (ClinicalTrials.gov Identifier: NCT02754999).  Other indications include vaso-occlusive crisis in adults with sickle cell disease and the reduction of delayed graft function following kidney transplantation.